AbbVie stock
ABBVNYSEAbbVie Inc., HealthcareISIN US00287Y1091
75Score 75 out of 100, Strong
Price and trend
82 / 100
Price history
+31% in one yearThe chart shows daily closes over 14 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 62).
The price is at its 52-week high. Largest decline in 14 years: 49% (January 2018 to August 2019).
Chart figures for advanced users
- SMA 50$274.15
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$240.04
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)62
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$197.38
- The lowest closing price of the last twelve months.
- Resistance$294.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AbbVie Inc. belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $521.41B, is number 3 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $61.16B (up 8.6% year on year) and earnings of $4.23B (down 1.2%).
- For fiscal 2026, analysts expect on average revenue of $67.69B (up 10.7%) and adjusted earnings per share of $13.97 (up 39.7%).
Show more
- MEQIRI Score 75 out of 100 (Strong): rank 66 of 714 in Healthcare, median 53.
- The P/E is 50.5 (Drug Manufacturers (General) median 25.6, own median of recent years 27.1).
- Our model puts fair value at $273.64, with the price 8% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 182% of earnings over the last 12 months.Fundamentals 100
- Reliable dividendNo dividend cut for 13 years.Capital allocation 69
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 100
Weaknesses
- Richly valuedP/E 50.5, Drug Manufacturers (General) median 25.6, own median 27.1.Valuation 31
Its standout strengths are fundamentals and profitability, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 74 to 75.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among the 100 largest stocks.
From 2016 to 2025, 4 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What lowers it
- solid fundamentals
- very large company
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $195.45 and expensive above $456.06 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $397.63 (cash-flow model) and $149.64 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $238.92, at 7.8% it would be $325.85.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10.7% on the twelve months before. Revenue has grown solidly since 2009, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 70%, operating 33%, net 7%. Last 12 months: net 16%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 30 Oct 2026EPS reported $3.82 (expected $3.73)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $13.97+0.4%
- Revenue
- $67.69B+0.1%
- Earnings per share
- $16.31−0.4%
- Revenue
- $73.69B+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −4.8%2026 guidance raised: net revenues about $67.6 billion (up $300 million), adjusted EPS $13.87 to $14.07.
“We now expect total net revenues of approximately $67.6 billion, an increase of $300 million This assumes a roughly 0.5% favorable impact from foreign exchange on full year sales growth.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 31 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $8.18M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Donoghoe NicholasSale
14 Aug 2026, EVP, CHIEF BUS/STRAT OFFICER
- Shares
- 32,710
- Price
- $250.00
- Value
- $8.18M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AbbVie
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 75
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Eli LillyLLY $1.35T85
- Johnson & JohnsonJNJ $675.03B75
- Roche HoldingROP.SW $391.92B77
- MerckMRK $362.86B68
- NovartisNOVN.SW $302.09B76
- AstraZenecaAZN $287.66B73
- AmgenAMGN $253.21B77
- Gilead SciencesGILD $210.52B58
ETFs that hold AbbVie
Held by 135 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 7.60% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 7.58% | 0.15% | €3.27B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 7.55% | 0.12% | €1.34B |
Show 5 more
| WisdomTree US High Dividend UCITS ETF AccWTD9 | 5.68% | 0.29% | €182.46M |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 5.67% | 0.18% | €837.43M |
| WisdomTree US Equity Income UCITS ETF EUR Hedged AccWTDY | 5.61% | 0.35% | €204.34M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 5.53% | 0.25% | €4.18B |
| WisdomTree US Quality Dividend Growth UCITS ETF USD AccWTDM | 4.10% | 0.33% | €721.26M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.